HNRNPC antibodies are monoclonal or polyclonal reagents that specifically bind to HNRNPC proteins (C1/C2 isoforms), which regulate RNA splicing, stabilization, and translation. Key development methods include:
Hybridoma Technology: Immunization with HNRNPC-derived peptides followed by B-cell fusion with myeloma cells (e.g., Clone 9G1 ).
Recombinant Production: Cloning variable regions of antibody heavy/light chains into expression vectors for large-scale purification .
Validation involves rigorous testing across six applications (ELISA, WB, IHC, IF, FC, IP) to confirm specificity for human HNRNPC .
HNRNPC antibodies have identified overexpression in 15+ cancers, including:
Liver Cancer: Positive HNRNPC expression correlates with tumor size, microvascular invasion, and reduced survival (HR = 1.8, p < 0.01) .
Prostate Cancer: Elevated HNRNPC links to higher Gleason scores (OR = 2.4) and suppressed immune infiltration (CD8+ T-cell reduction: 35%) .
Cervical Cancer: HNRNPC promotes lymph node metastasis (p < 0.001) via FOXM1 splicing .
Proliferation Assays: HNRNPC knockdown reduces HCC cell viability by 60% (CCK-8 assay) .
Invasion/Migration: Transwell assays show 70% inhibition in HNRNPC-silenced cervical cancer cells .
Immune Microenvironment: IHC reveals HNRNPC negatively correlates with ImmuneScore in 23/25 cancers .